文献速递胸部肿瘤

基于纵向游离DNA二代测序的前瞻性研究:埃万妥单抗治疗EGFR外显子20插入突变非小细胞肺癌的生物标志物与耐药机制

Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab.
PubMed 文献 · Eur J Cancer · 2025-07-10

该前瞻性研究对30例EGFR外显子20插入突变非小细胞肺癌患者在接受埃万妥单抗治疗期间纵向采集血浆,使用Guardant OMNI进行cf-NGS分析。基线EGFR ex20ins变异等位基因频率(VAF)<1%的患者相比VAF≥1%者客观缓解率更高(45.4% vs 35.7%)、持久临床获益率更高(81.8% vs 21.4%)、无进展生存期更长(16.5 vs 2.6个月,HR 0.40,p<0.01)。研究还发现获得性耐药机制,并强调早期ctDNA动态变化对疗效和长期结局的预测价值。

要点

  • 基线EGFR ex20ins VAF<1%者较VAF≥1%者PFS更长(16.5 vs 2.6个月,HR 0.40,p<0.01)。
  • 基线VAF<1%者客观缓解率45.4% vs 35.7%,持久临床获益率81.8% vs 21.4%。
  • 合并EGFR扩增者PFS显著更短(11.1 vs 2.7个月,HR 0.35,p<0.05)。

核心结论

  • 基线EGFR ex20ins VAF对埃万妥单抗治疗具有显著预测价值。
  • 治疗期间ctDNA VAF变化提示早期ctDNA动态可作为疗效和长期结局的关键预测因素,可能为治疗策略提供信息。

研究设计与样本

  • 前瞻性纵向收集30例经PCR或NGS确认的EGFR ex20ins患者接受埃万妥单抗治疗的血浆样本。
  • 采用Guardant OMNI研究用检测进行分子谱分析,共对25例患者的62份样本完成cf-NGS分析。

主要发现

  • 基线EGFR ex20ins VAF<1%组(n=11)相比VAF≥1%组(n=14)客观缓解率为45.4% vs 35.7%,持久临床获益率为81.8% vs 21.4%。
  • 基线VAF<1%组相比VAF≥1%组PFS为16.5 vs 2.6个月(HR 0.40,p<0.01)。
  • 最常见的合并突变为TP53(n=14,56.0%),与临床结局无相关性。
  • 合并EGFR扩增(n=9,36.0%)者PFS显著更短(11.1 vs 2.7个月,HR 0.35,p<0.05)。
  • 配对分析显示,基于EGFR ex20ins VAF在基线与治疗期间的动态变化,PFS存在显著差异,并发现若干获得性耐药机制。

关键数值与推荐

  • 基线EGFR ex20ins VAF<1%组客观缓解率45.4%、持久临床获益率81.8%、PFS 16.5个月。
  • 基线EGFR ex20ins VAF≥1%组客观缓解率35.7%、持久临床获益率21.4%、PFS 2.6个月(HR 0.40,p<0.01)。
  • 合并EGFR扩增组PFS 2.7个月 vs 无合并EGFR扩增组11.1个月(HR 0.35,p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been little investigation of predictive biomarkers and resistance mechanisms of amivantamab, an EGFR, and MET targeting bispecific antibody in EGFR ex20ins. Here, we investigated the correlation of molecular profile with clinical outcome using cell-free NGS (cf-NGS) in patients treated with amivantamab. METHODS: Plasma samples from PCR or NGS-confirmed EGFR ex20ins patients (n = 30) treated with amivantamab were prospectively and longitudinally collected for analysis. The Guardant OMNI research-use-only assay was used for molecular profiling. RESULTS: cfNGS analysis was performed on 62 samples from 25 patients. Baseline cfDNA-based NGS results demonstrated that patients with an EGFR ex20ins variant allele frequency (VAF) < 1 % (n = 11) showed higher objective response rate (45.4 vs 35.7 %), durable clinical benefit ratio (81.8 vs 21.4 %), and longer progression-free survival (PFS) (16.5 vs 2.6 months, hazard ratio [HR] 0.40, p < 0.01) compared to those with VAF ≥ 1 % (n = 14). The most common concurrent alteration was TP53 (n = 14, 56.0 %) which showed no correlation with clinical outcome while concomitant EGFR amplification (n = 9, 36.0 %) showed significantly shorter PFS (11.1 vs 2.7 months, HR 0.35, p < 0.05). Paired analysis showed a significant difference in PFS based on the dynamics of EGFR ex20ins VAF compared to the baseline and during treatment. Additionally, we identified several acquired resistance mechanisms to amivantamab. CONCLUSIONS: Our findings underscore the significant predictive value of baseline EGFR ex20ins VAF for amivantamab treatment. Furthermore, changes in ctDNA VAF during treatment emphasize the role of early ctDNA dynamics as critical predictors of therapeutic response and long-term outcomes, which may inform treatment strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Park GH, Park S, Kim H, et al. Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab. Eur J Cancer. 2025. PMID: 40651388. doi:10.1016/j.ejca.2025.115631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。